Assessment of serum amylase, lipase and associated factors among patients with visceral Leishmaniasis treatment with Sodium Stibogluconate /Paromomycin treatment

---

Tiget Ayelgn Mengstie

University of Gondar college of Medicine and health science school of Medicine,Ethiopia

: J Pharm Drug Deliv Res

Abstract

---

Visceral leishmaniasis\(VL) is a life-threatening parasitic disease next to malaria, which is responsible for the death of 50,000 patients annually. Sodium stibogluconate and paromomycin combined therapy are recommended to treat VL in East Africa. However, the adverse effect of those combined drugs is not welldefined in the study area. Therefore, the purpose of this study was to assess serum amylase, lipase, and associated factors among patients with VL treatment with those combined drugs. Hospital-based cross-sectional study was conducted from February to September 2020 G.C. Simple random sampling technique was utilized to select study participants. Descriptive data was presented by tables, charts and graphs. Data was cleared, entered by Epi-data version 3.1 then transfer to STATA 14.1 SE version, for analysis paired t-test was used, for factors correlation and multivariate regression was used. The mean ± SD level of serum amylase after treatment showed a statistically significant elevation (P<0.001) as compared to its level before treatment. Similarly, the mean ± SD level of serum lipase after treatment showed a statistically significant elevation (P<0.001) as compared to its level before treatment. There was also significant association between age and baseline of these enzyme as compared test of cure. As conclusion, there was an increase in mean serum amylase and lipase after a patient taking combined drugs. Consequently, the elevated result of these biochemical profiles was mainly associated with drug induced adverse effect and associated risk factors in VL patients.

Biography

---

Jeffrey Baum is currently a fourth-year medical student in New York Medical College in Westchester, NY. After earning his Master’s degree in Talmudic Law, he went to medical school to pursue his passion for scholastic research and clinical medicine. He will be graduating in May of 2022 as a senior member of the Alpha Omega Alpha Medical Honor Society.